Claims

1. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof for use as a medicament, wherein

R^1 is -OH;

R^2 is $-S(O)_2CF_3$;

R^3 is $C_{1\text{-}2}$alkyl, wherein said $C_{1\text{-}2}$ alkyl is optionally substituted with one or more R^{40};

R^4 is $C_{1\text{-}2}$alkyl, wherein said $C_{1\text{-}2}$ alkyl is optionally substituted with one or more R^{40};

R^{40} in each occurrence is selected from $-OR^{40a}$ and $-OP(=O)(OH)_2$;

R^{40a} is H.

2. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 1, wherein the compound has the following stereochemistry:



3. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 2, wherein the compound is 4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-ylamino)-3-trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

4. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 2, wherein the compound is 4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-ylamino)-3-trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

5. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 2, wherein the compound is 2-(((*R*)-3-(4-(*N*-(4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzoyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)(methyl)amino)ethyl dihydrogen phosphate.

6. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 2, wherein the compound 4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-(ethyl(2-hydroxyethyl)amino)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

7. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 2, wherein the compound is 2-(((*R*)-3-(4-(*N*-(4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzoyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)(ethyl)amino)ethyl dihydrogen phosphate.

8. A compound of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt thereof for use in the treatment of cancer in a warm-blooded animal, wherein

R^1 is -OH;

R^2 is $-S(O)_2CF_3$;

R^3 is C_{1-2}alkyl, wherein said C_{1-2} alkyl is optionally substituted with one or more R^{40};

R^4 is C_{1-2}alkyl, wherein said C_{1-2} alkyl is optionally substituted with one or more R^{40};

R^{40} in each occurrence is selected from $-OR^{40a}$ and $-OP(=O)(OH)_2$;

R^{40a} is H.

9. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound has the following stereochemistry:



10. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound is 4-(4-((*R*)-(4'-chlorobiphenyl-2-

yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-ylamino)-3-trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

11. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound is 4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-((2-hydroxyethyl)(methyl)amino)-1-(phenylthio)butan-2-ylamino)-3-trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

12. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound is 2-(((*R*)-3-(4-(*N*-(4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzoyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)(methyl)amino)ethyl dihydrogen phosphate.

13. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound 4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)-*N*-(4-((*R*)-4-(ethyl(2-hydroxyethyl)amino)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)benzamide.

14. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the compound is 2-(((*R*)-3-(4-(*N*-(4-(4-((*R*)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzoyl)sulfamoyl)-2-(trifluoromethylsulfonyl)phenylamino)-4-(phenylthio)butyl)(ethyl)amino)ethyl dihydrogen phosphate.

15. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the cancer is bladder cancer, breast cancer, colon cancer, ovarian cancer, AML, diffuse large B-cell lymphoma (DLBCL), CLL, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), including the non-squamous and squamous subtypes, pancreatic cancer, prostate cancer, non-Hodgkin's lymphomas, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Mantle Zone Lymphoma (MZL), Hairy Cell Leukemia (HCL), and Peripheral T-cell Lymphoma (PTCL).

16. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the cancer is diffuse large B-cell lymphoma (DLBCL).

17. The compound of Formula (I) or the pharmaceutically acceptable salt thereof for use according to claim 8, wherein the cancer is non-small cell lung cancer (NSCLC).